Literature DB >> 29614673

Findings from the Swedish Study on Familial Alzheimer's Disease Including the APP Swedish Double Mutation.

Steinunn Thordardottir1, Caroline Graff1,2.   

Abstract

This is a brief summary of the findings from the Swedish study on familial Alzheimer's disease (FAD). Similar to other FAD studies, it includes prospective assessments of cognitive function, tissue sampling, and technical analyses such as MRI and PET. This 24-year-old study involves 69 individuals with a 50% risk of inheriting a disease-causing mutation in presenilin 1 (PSEN1 H163Y or I143T), or amyloid precursor protein (the Swedish APP or the arctic APP mutation) who have made a total of 169 visits. Our results show the extraordinary power in this study design to unravel the earliest changes in preclinical AD. The Swedish FAD study will continue and future research will focus on disentangling the order of pathological change using longitudinal data as well as modeling the changes in patient derived cell systems.

Entities:  

Keywords:  Alzheimer’s disease; biomarkers; cerebrospinal fluid; genetics; neuroimaging; neuropsychology

Mesh:

Substances:

Year:  2018        PMID: 29614673     DOI: 10.3233/JAD-179922

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  2 in total

1.  Decoupling the Effects of the Amyloid Precursor Protein From Amyloid-β Plaques on Axonal Transport Dynamics in the Living Brain.

Authors:  Christopher S Medina; Taylor W Uselman; Daniel R Barto; Frances Cháves; Russell E Jacobs; Elaine L Bearer
Journal:  Front Cell Neurosci       Date:  2019-12-03       Impact factor: 5.505

2.  The Links between Cardiovascular Diseases and Alzheimer's Disease.

Authors:  Jerzy Leszek; Elizaveta V Mikhaylenko; Dmitrii M Belousov; Efrosini Koutsouraki; Katarzyna Szczechowiak; Małgorzata Kobusiak-Prokopowicz; Andrzej Mysiak; Breno Satler Diniz; Siva G Somasundaram; Cecil E Kirkland; Gjumrakch Aliev
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.363

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.